History
A list of downloadable documents created during development.
Review proposal consultation
Diabetes (type 2) ? dapagliflozin: equality impact assessment - guidance review
-
Diabetes (type 2) ? dapagliflozin: equality impact assessment - guidance review
-
Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping (PDF 32 KB)
Diabetes (type 2) - dapagliflozin: final appraisal determination
-
Diabetes (type 2) - dapagliflozin: final appraisal determination information
-
Diabetes (type 2) - dapagliflozin: final appraisal determination document
-
Diabetes (type 2) - dapagliflozin: final appraisal determination document (PDF 480 KB)
-
Diabetes (type 2) - dapagliflozin: evaluation report information
-
Diabetes (type 2) - dapagliflozin: evaluation report (PDF 4.49 MB)
Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form
-
Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form
-
Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form (PDF 51 KB)
Diabetes (type 2) - dapagliflozin: appraisal consultation
-
Diabetes (type 2) - dapagliflozin: appraisal consultation
-
Diabetes (type 2) - dapagliflozin: appraisal consultation document information
-
Diabetes (type 2) - dapagliflozin: evaluation report
-
Diabetes (type 2) - dapagliflozin: pre-briefing meeting
-
Diabetes (type 2) - dapagliflozin: pre-briefing meeting (PDF 749 KB)
-
Diabetes (type 2) - dapagliflozin: Evidence Review Group report
-
Diabetes (type 2) - dapagliflozin: Evidence Review Group report
-
Diabetes (type 2) - dapagliflozin: Evidence Review Group report (PDF 1.35 MB)
-
Diabetes (type 2) - dapagliflozin: changes to the ERG report
-
Diabetes (type 2) - dapagliflozin: changes to the ERG report (PDF 281 KB)
-
Diabetes (type 2) - dapagliflozin: Decision Support Unit report
-
Diabetes (type 2) - dapagliflozin: Decision Support Unit report (PDF 875 KB)
-
Diabetes (type 2) - dapagliflozin: Evidence Review Group report - factual accuracy check
-
-
Diabetes (type 2) - dapagliflozin: ERG BMI analyses
-
Diabetes (type 2) - dapagliflozin: ERG BMI analyses (PDF 105 KB)
-
Diabetes (type 2) - dapagliflozin: manufacturer submission
-
Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca
-
Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca (PDF 5.56 MB)
-
Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca addendum
-
Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca addendum (PDF 741 KB)
-
Diabetes (type 2) - dapagliflozin: clarification
-
Diabetes (type 2) - dapagliflozin: NICE clarification letter
-
Diabetes (type 2) - dapagliflozin: NICE clarification letter (PDF 102 KB)
-
Diabetes (type 2) - dapagliflozin: Manufacturer response to the NICE clarification letter
-
-
Diabetes (type 2) - dapagliflozin: ERG's additional clarification questions and manufacturer responses
-
-
Diabetes (type 2) - dapagliflozin: patient group, professional group and NHS organisation submission statements
-
Diabetes (type 2) - dapagliflozin: Royal College of Nursing
-
Diabetes (type 2) - dapagliflozin: Royal College of Nursing (PDF 11 KB)
-
Diabetes (type 2) - dapagliflozin: Royal College of Pathologists
-
Diabetes (type 2) - dapagliflozin: Royal College of Pathologists (PDF 51 KB)
-
Diabetes (type 2) - dapagliflozin: NHS Middlesbrough
-
Diabetes (type 2) - dapagliflozin: NHS Middlesbrough (PDF 57 KB)
-
Diabetes (type 2) - dapagliflozin: expert written personal statements
-
Diabetes (type 2) - dapagliflozin: Kilpatrick Appendix D - clinical specialist statement
-
Diabetes (type 2) - dapagliflozin: Kilpatrick Appendix D - clinical specialist statement (PDF 33 KB)
-
Diabetes (type 2) - dapagliflozin: Kuti Appendix K - patient/carer expert statement
-
Diabetes (type 2) - dapagliflozin: Kuti Appendix K - patient/carer expert statement (PDF 214 KB)
-
Diabetes (type 2) - dapagliflozin: Linton - Appendix K NHS-Commissioning expert statement declaration
-
-
Diabetes (type 2) - dapagliflozin: Moulton - Appendix K - Patient/carer expert statement
-
-
Diabetes (type 2) - dapagliflozin: Ononeze - Appendix K NHS-Commissioning expert statement declaration
-
-
Diabetes (type 2) - dapagliflozin: Winocour - Appendix D clinical specialist statement
-
Diabetes (type 2) - dapagliflozin: Winocour - Appendix D clinical specialist statement (PDF 81 KB)
Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping
-
Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping
-
Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping (PDF 32 KB)
Diabetes (type 2) - dapagliflozin: appendix B - final scope
-
Diabetes (type 2) - dapagliflozin: appendix B - final scope
-
Diabetes (type 2) - dapagliflozin: appendix B - final scope (PDF 67 KB)
Diabetes (type 2) - dapagliflozin: appendix C - final matrix
-
Diabetes (type 2) - dapagliflozin: appendix C - final matrix
-
Diabetes (type 2) - dapagliflozin: appendix C - final matrix (PDF 33 KB)
Diabetes (type 2) - dapagliflozin: appendix D - comments table
-
Diabetes (type 2) - dapagliflozin: appendix D - comments table
-
Diabetes (type 2) - dapagliflozin: appendix D - comments table (PDF 227 KB)
Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012
-
Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012
-
Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012
-
Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012
-
Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012 (PDF 39 KB)
Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011
-
Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011
-
Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011
-
Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011
-